Asthma symptoms worsened in children in Vermont and upstate New York exposed to smoke from Canadian wildfires, according to a recent study by UVM.

Calling AQI–lung damage 'not proven' reflects missing long-term Indian studies, not absence of harm, a senior pulmonologist ...

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...

Kolkata: A surge in pneumonia and COPD patients has left several private hospitals close to full occupancy, leading to a ...

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...

FDA approves 2-dose biologic Exdensur for severe eosinophilic asthma in patients 12 and older, reducing exacerbations and hospital visits.

Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two ...

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | Tuesday ...

The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

GSK Plc said it won US approval for a drug to treat severe asthma, boosting its prospects as a potential blockbuster.